Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
0%(0 trials)

Phase Distribution

Ph early_phase_1
1
25%
Ph phase_4
1
25%
Ph not_applicable
1
25%

Phase Distribution

1

Early Stage

0

Mid Stage

1

Late Stage

Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
N/ANon-phased studies
1(33.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(2)
Other(2)

Detailed Status

unknown2
Completed2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (33.3%)
Phase 41 (33.3%)
N/A1 (33.3%)

Trials by Status

unknown250%
completed250%

Recent Activity

0 active trials
Showing 4 of 4
completednot_applicable

PET-MR Imaging of Coronary Atherothrombosis

NCT03618303
completedearly_phase_1

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

NCT02683824
unknown

Evaluating Gut Imaging and Stool Biomarkers in Patients With Scleroderma-associated Gastrointestinal Disease

NCT04630782
unknownphase_4

Metformin And Longevity

NCT02511665

Clinical Trials (4)

Showing 4 of 4 trials
NCT03618303Not Applicable

PET-MR Imaging of Coronary Atherothrombosis

Completed
NCT02683824Early Phase 1

Integrin Alpha-v-Beta and [18F]-R01-MG-F2 PET/CT in Measuring Response in Patients With Pancreatic Cancer and Healthy Volunteers

Completed
NCT04630782

Evaluating Gut Imaging and Stool Biomarkers in Patients With Scleroderma-associated Gastrointestinal Disease

Unknown
NCT02511665Phase 4

Metformin And Longevity

Unknown

All 4 trials loaded

Drug Details

Intervention Type
DIAGNOSTIC TEST
Total Trials
4